HUE058323T2 - Egy BTK-inhibitor rák kezelésében történõ alkalmazásra - Google Patents
Egy BTK-inhibitor rák kezelésében történõ alkalmazásraInfo
- Publication number
- HUE058323T2 HUE058323T2 HUE16804956A HUE16804956A HUE058323T2 HU E058323 T2 HUE058323 T2 HU E058323T2 HU E16804956 A HUE16804956 A HU E16804956A HU E16804956 A HUE16804956 A HU E16804956A HU E058323 T2 HUE058323 T2 HU E058323T2
- Authority
- HU
- Hungary
- Prior art keywords
- treating cancer
- btk inhibitor
- btk
- inhibitor
- cancer
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562250575P | 2015-11-04 | 2015-11-04 | |
| US201662296143P | 2016-02-17 | 2016-02-17 | |
| US201662341189P | 2016-05-25 | 2016-05-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUE058323T2 true HUE058323T2 (hu) | 2022-07-28 |
Family
ID=57442803
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE16804956A HUE058323T2 (hu) | 2015-11-04 | 2016-11-04 | Egy BTK-inhibitor rák kezelésében történõ alkalmazásra |
Country Status (22)
| Country | Link |
|---|---|
| US (3) | US20170119766A1 (hu) |
| EP (2) | EP3371165B1 (hu) |
| JP (3) | JP6913100B2 (hu) |
| KR (1) | KR20180073599A (hu) |
| CN (1) | CN108779095A (hu) |
| AU (3) | AU2016349584B9 (hu) |
| BR (1) | BR112018007604B1 (hu) |
| CA (1) | CA3001735A1 (hu) |
| DK (1) | DK3371165T3 (hu) |
| ES (1) | ES2912059T3 (hu) |
| HU (1) | HUE058323T2 (hu) |
| IL (2) | IL293093B1 (hu) |
| LT (1) | LT3371165T (hu) |
| MX (2) | MX2018005461A (hu) |
| NZ (1) | NZ741293A (hu) |
| PL (1) | PL3371165T3 (hu) |
| RS (1) | RS63146B1 (hu) |
| RU (2) | RU2765154C2 (hu) |
| SG (2) | SG10202005292UA (hu) |
| SI (1) | SI3371165T1 (hu) |
| TW (2) | TW202320784A (hu) |
| WO (1) | WO2017079542A1 (hu) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ741293A (en) * | 2015-11-04 | 2023-06-30 | Merck Patent Gmbh | Methods for treating cancer using pyrimidine and pyridine compounds with btk inhibitory activity |
| BR112018007517B1 (pt) * | 2015-11-17 | 2023-09-26 | Merck Patent Gmbh | Uso decompostos de pirimidina e piridina com atividade inibidora de btk para preparar medicamentos para tratar esclerose múltipla |
| WO2018204532A1 (en) * | 2017-05-03 | 2018-11-08 | Vivace Therapeutics, Inc. | Non-fused tricyclic compounds |
| WO2019243223A1 (en) | 2018-06-19 | 2019-12-26 | Merck Patent Gmbh | Novel crystalline forms of 1-(4-{[6-amino-5-(4-phenoxy-phenyl)-pyrimidin-4-ylamino]-methyl}-4-fluoro-piperidin-1-yl)-propenone, salt forms thereof, and processes to obtain |
| US20210308140A1 (en) | 2018-07-25 | 2021-10-07 | Novartis Ag | Nlrp3 inflammasome inhibitors |
| AR119731A1 (es) | 2019-05-17 | 2022-01-05 | Novartis Ag | Inhibidores del inflamasoma nlrp3 |
| UY39377A (es) | 2020-08-14 | 2022-03-31 | Novartis Ag | Derivados de espiropiperidinilo sustituidos con heteroarilo y usos farmacéuticos de los mismos |
| CN112250666B (zh) * | 2020-10-09 | 2022-01-14 | 广东东阳光药业有限公司 | 取代的嘧啶类化合物及其用途 |
| TW202304889A (zh) * | 2021-04-03 | 2023-02-01 | 大陸商海南耀臻生物醫藥科技有限公司 | 作為fgfr抑制劑的雜環化合物及其應用 |
| US11866421B2 (en) | 2021-05-31 | 2024-01-09 | Epigen Biosciences, Inc. | Pyrimidine and pyridine amine compounds and usage thereof in disease treatment |
| WO2023247774A1 (en) | 2022-06-24 | 2023-12-28 | Merck Patent Gmbh | Treatment regimen for autoimmune diseases and inflammatory diseases |
| TW202406550A (zh) | 2022-08-03 | 2024-02-16 | 瑞士商諾華公司 | Ｎｌｒｐ３炎性小體抑制劑 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19649896A1 (de) * | 1996-12-02 | 1998-06-04 | Henkel Kgaa | Geformte Seifenprodukte |
| TW520362B (en) * | 1996-12-05 | 2003-02-11 | Amgen Inc | Substituted pyrimidine compounds and pharmaceutical composition comprising same |
| EP2786995A1 (en) * | 2004-03-30 | 2014-10-08 | Vertex Pharmaceuticals Incorporated | Azaindoles useful as inhibitors of JAK and other protein kinases |
| JP2011500823A (ja) * | 2007-10-22 | 2011-01-06 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | Ｐｉ３キナーゼ阻害物質としてのピリドスルホンアミド誘導体 |
| CL2009001152A1 (es) * | 2008-05-13 | 2009-10-16 | Array Biopharma Inc | Compuestos derivados de n-(4-(cicloalquilo nitrogenado-1-il)-1h-pirrolo[2,3-b]piridin-3-il)amida, inhibidores de cinasa; proceso de preparacion; composicion farmaceutica; y su uso para el tratamiento de una enfermedad proliferativa. |
| JP2014517016A (ja) * | 2011-06-10 | 2014-07-17 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｂｔｋ阻害活性を有するピリミジンおよびピリミジン化合物の組成物と製造方法 |
| TW201414734A (zh) * | 2012-07-10 | 2014-04-16 | Takeda Pharmaceutical | 氮雜吲哚衍生物 |
| WO2014093230A2 (en) * | 2012-12-10 | 2014-06-19 | Merck Patent Gmbh | Compositions and methods for the production of pyrimidine and pyridine compounds with btk inhibitory activity |
| WO2014151620A1 (en) * | 2013-03-14 | 2014-09-25 | Boehringer Ingelheim International Gmbh | 5-thiazolecarboxamide dervatives and their use as btk inhibitors |
| MY184292A (en) * | 2013-09-22 | 2021-03-30 | Sunshine Lake Pharma Co Ltd | Substituted aminopyrimidine compounds and methods of use |
| GB201404987D0 (en) * | 2014-03-20 | 2014-05-07 | Redx Pharma Ltd | Compounds |
| NZ741293A (en) * | 2015-11-04 | 2023-06-30 | Merck Patent Gmbh | Methods for treating cancer using pyrimidine and pyridine compounds with btk inhibitory activity |
| BR112018007517B1 (pt) * | 2015-11-17 | 2023-09-26 | Merck Patent Gmbh | Uso decompostos de pirimidina e piridina com atividade inibidora de btk para preparar medicamentos para tratar esclerose múltipla |
-
2016
- 2016-11-04 NZ NZ741293A patent/NZ741293A/en unknown
- 2016-11-04 DK DK16804956.7T patent/DK3371165T3/da active
- 2016-11-04 KR KR1020187013350A patent/KR20180073599A/ko unknown
- 2016-11-04 RS RS20220376A patent/RS63146B1/sr unknown
- 2016-11-04 ES ES16804956T patent/ES2912059T3/es active Active
- 2016-11-04 PL PL16804956T patent/PL3371165T3/pl unknown
- 2016-11-04 TW TW111140026A patent/TW202320784A/zh unknown
- 2016-11-04 EP EP16804956.7A patent/EP3371165B1/en active Active
- 2016-11-04 MX MX2018005461A patent/MX2018005461A/es unknown
- 2016-11-04 BR BR112018007604-0A patent/BR112018007604B1/pt active IP Right Grant
- 2016-11-04 IL IL293093A patent/IL293093B1/en unknown
- 2016-11-04 RU RU2018120153A patent/RU2765154C2/ru active
- 2016-11-04 SI SI201631518T patent/SI3371165T1/sl unknown
- 2016-11-04 CA CA3001735A patent/CA3001735A1/en active Pending
- 2016-11-04 AU AU2016349584A patent/AU2016349584B9/en active Active
- 2016-11-04 US US15/343,570 patent/US20170119766A1/en not_active Abandoned
- 2016-11-04 RU RU2022100782A patent/RU2022100782A/ru unknown
- 2016-11-04 JP JP2018543055A patent/JP6913100B2/ja active Active
- 2016-11-04 CN CN201680077336.5A patent/CN108779095A/zh active Pending
- 2016-11-04 SG SG10202005292UA patent/SG10202005292UA/en unknown
- 2016-11-04 TW TW105135943A patent/TWI783915B/zh active
- 2016-11-04 SG SG11201802927VA patent/SG11201802927VA/en unknown
- 2016-11-04 EP EP22152631.2A patent/EP4014977A1/en active Pending
- 2016-11-04 HU HUE16804956A patent/HUE058323T2/hu unknown
- 2016-11-04 WO PCT/US2016/060508 patent/WO2017079542A1/en active Application Filing
- 2016-11-04 LT LTEPPCT/US2016/060508T patent/LT3371165T/lt unknown
-
2018
- 2018-04-26 IL IL258979A patent/IL258979B/en unknown
- 2018-04-30 MX MX2021015826A patent/MX2021015826A/es unknown
-
2020
- 2020-03-05 US US16/809,850 patent/US11491153B2/en active Active
-
2021
- 2021-04-16 US US17/232,383 patent/US20210244736A1/en active Pending
- 2021-07-09 JP JP2021113947A patent/JP7295169B2/ja active Active
- 2021-08-02 AU AU2021211982A patent/AU2021211982B2/en active Active
-
2023
- 2023-05-30 AU AU2023203377A patent/AU2023203377A1/en active Pending
- 2023-06-08 JP JP2023094794A patent/JP2023105214A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUE058323T2 (hu) | Egy BTK-inhibitor rák kezelésében történõ alkalmazásra | |
| IL272724B (en) | Gemcitabine drug inhibitors | |
| IL259479B (en) | Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor | |
| PT3500299T (pt) | Combinação de zanubrutinib com um anticorpo anti-cd20 ou anti-pd-1 para utilização no tratamento do cancro | |
| HK1249469A1 (zh) | 用RORγ抑制劑治療癌症的方法 | |
| IL251630A0 (en) | Combined therapy for use in cancer treatment | |
| SG11201705810YA (en) | Device for treating a surface | |
| IL249231A0 (en) | Pharmaceutical combinations for cancer treatment | |
| IL251411A0 (en) | A method for treating cancer | |
| HK1254258A1 (zh) | 使用阿吡莫德治療癌症的方法 | |
| RS61745B1 (sr) | Inhibitori farneziltransferaze za upotrebu u tretiranju kancera | |
| IL272027B (en) | Endothelial prodrugs for use in cancer treatment. | |
| PT3164394T (pt) | Inibidores gls1 para o tratamento de doenças | |
| HK1252172A1 (zh) | 用於使用stat3途徑抑制劑和激酶抑制劑治療癌症的方法 | |
| SG11201709818WA (en) | Device for treating a surface | |
| SI3463436T1 (sl) | Cepivo v kombinaciji z zaviralcem imunske kontrolne točke za uporabo pri zdravljenju raka | |
| LT3518911T (lt) | Rad1901, skirtas naudoti kiaušidžių vėžio gydymui | |
| AP2016009066A0 (en) | A drug for treating cancer | |
| GB201411111D0 (en) | bis-Pyridazine compounds and their use in treating cancer | |
| GB201414904D0 (en) | Materials and methods for treating cancer |